References
- 1
Vader J P, Burnand B, Froehlich F, et al.
The European Panel on Appropriateness of Gastrointestinal Endoscopy (EPAGE): Project
and Methods.
Endoscopy.
1999;
31
572-578
- 2
Vader J P, Froehlich F, Dubois R W, et al.
The European Panel on Appropriateness of Gastrointestinal Ensocopy (EPAGE): Conclusions
and WWW site.
Endoscopy.
1999;
31
687-694
- 3
Morrissey J F, Reichelderfer M.
Gastrointestinal endoscopy (2).
N Engl J Med.
1991;
325
1214-1222
- 4
Colin-Jones D G.
Management of dyspepsia: report of a working party.
Lancet.
1988;
1
576-579
- 5
Talley N J, Phillips S F.
Non-ulcer dyspepsia: potential causes and pathophysiology.
Ann Intern Med.
1988;
108
865-879
- 6
Barbara L, Camilleri M, Corinaldesi R, et al.
Definition and investigation of dyspepsia. Consensus of an international ad hoc working
party.
Dig Dis Sci.
1989;
34
1272-1276
- 7
Malfertheiner P, McColl K, Baldi F, et al.
Update on Helicobacter pylori research. Dyspepsia.
Eur J Gastroenterol Hepatol.
1997;
9
624-625
- 8
Agreus L, Engstrand L, Svardsudd K, et al.
Helicobacter pylori seropositivity among Swedish adults with and without abdominal
symptoms. A population-based epidemiologic study.
Scan J Gastroenterol.
1995;
30
752-757
- 9
Veldhuyzen van Zanten S J, Tytgat K M, Pollak P T, et al.
Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia
and Helicobacter pylori associated gastritis?.
J Clin Epidemiol.
1993;
46
273-279
- 10
Bochud M, Gonvers J J, Vader J P, et al.
Appropriateness of gastroscopy: Gastroesophageal reflux disease.
Endoscopy.
1999;
31
596-603
- 11
Talley N J, Weaver A L, Zinsmeister A R, et al.
Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal
disorders.
Am J Epidemiol.
1992;
136
165-177
- 12
Talley N J, Zinsmeister A R, Schleck C D, et al.
Dyspepsia and dyspepsia subgroups: a population-based study.
Gastroenterology.
1992;
102
1259-1268
- 13
Jones R H, Lydeard S E, Hobbs F D, et al.
Dyspepsia in England and Scotland.
Gut.
1990;
3
401-405
- 14
Knill-Jones R P.
Geographical differences in the prevalence of dyspepsia.
Scan J Gastroenterol.
1991;
26
17-24
- 15
Jones R.
Dyspeptic symptoms in the community.
Gut.
1989;
30
893-898
- 16
Johnsen R, Bernersen B, Straume B, et al.
Prevalences of endoscopic and histological findings in subjects with and without dyspepsia.
BMJ.
1991;
302
749-752
- 17
Vaira D, Stanghellini V, Menegatti M, et al.
Prospective screening of dyspeptic patients by Helicobacter pylori serology: a safe
policy? The Italian Helicobacter pylori Study Group.
Endoscopy.
1997;
29
595-601
- 18
Patel P, Mendall M A, Khulusi S, et al.
Salivary antibodies to Helicobacter pylori: screening dyspeptic patients before endoscopy.
Lancet.
1994;
344
511-512
- 19
Sobala G M, Crabtree J E, Pentith J A, et al.
Screening dyspepsia by serology to Helicobacter pylori.
Lancet.
1991;
338
94-96
- 20
Heikkinen M, Pikkarainen P, Takala J, et al.
Etiology of dyspepsia: four hundred unselected consecutive patients in general practice.
Scan J Gastroenterol.
1995;
30
519-523
- 21
Mansi C, Mela G S, Savarino V, et al.
Open access endoscopy: a large-scale analysis of its use in dyspeptic patients.
J Clin Gastroenterol.
1993;
16
149-153
- 22
Bernersen B, Johnsen R, Bostad L, et al.
Is Helicobacter pylori the cause of dyspepsia?.
BMJ.
1992;
304
1276-1279
- 23
Talley N J, Weaver A L, Tesmer D L, et al.
Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy.
Gastroenterology.
1993;
105
1378-1386
- 24
Hansen J M, Bytzer P, Bondesen S, et al.
Efficacy and outcome of an open access endoscopy service.
Dan Med Bull .
1991;
38
288-290
- 25
Fraser A G, Ali M R, McCullough S, et al.
Diagnostic tests for Helicobacter pylori - can they help select patients for endoscopy?.
New Zealand Medical Journal.
1996;
109
95-98
- 26
Carpenter H A, Talley N J.
Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy
from gastritis.
Gastroenterology.
1995;
108
917-924
- 27
Richter J E.
Dyspepsia: organic causes and differential characteristics from functional dyspepsia.
(Review).
Scand J Gastroenterol Suppl.
1991;
182
11-16
- 28
Williams B, Luckas M, Ellingham J H, et al.
Do young patients with dyspepsia need investigation?.
Lancet.
1988;
2
1349-1351
- 29
Bytzer P, Schaffalitzky de Muckadell O B.
Prediction of major pathologic conditions in dyspeptic patients referred for endoscopy.
A prospective validation study of a scoring system.
Scan J Gastroenterol.
1992;
27
987-992
- 30
Kalra L, Price W R, Jones B J, Hamlyn A N.
Open access fibresigmoidoscopy: a comparative audit of efficacy.
Br Med J Clin Res Ed.
1994; 1998;
6629
1095-1096
- 31
Mansi C, Mela G S, Pasini D, et al.
Patterns of dyspepsia in patients with no clinical evidence of organic diseases.
Dig Dis Sci.
1990;
35
1452-1458
- 32
Bytzer P, Hansen J M, Havelund T, et al.
Predicting endoscopic diagnosis in the dyspeptic patient: the value of clinical judgement.
Eur J Gastroenterol Hepatol.
1996;
8
359-363
- 33
Adang R P, Ambergen A W, Talmon J L, et al.
The discriminative value of patient characteristics and dyspeptic symptoms for upper
gastrointestinal endoscopic findings: A study on the clinical presentation of 1147
patients.
Digestion.
1996;
57
118-134
- 34
Heading R C, Wager E, Tooley P J.
Reliability of symptom assessment in dyspepsia.
Eur J Gastroenterol Hepatol.
1997;
9
779-781
- 35
Davenport P M, Morgan A G, Darnborough A, de Dombal F T.
Can preliminary screening of dyspeptic patients allow more effective use of investigational
techniques?.
Brit Med J Clin Res Ed.
1994; 1985;
6463
217-220
- 36
Numans M E, Van der Graaf Y, de Wit N J, et al.
How much ulcer is ulcer-like? Diagnostic determinants of peptic ulcer in open access
gastroscopy.
Family Practice.
1994;
11
382-388
- 37
Muris J W, Starmans R, Pop P.
Discriminant value of symptoms in patients with dyspepsia.
J Fam Pract.
1994;
38
139-143
- 38
Dooley C P, Cohen H, Fitzgibbons P L, et al.
Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic
persons.
N Engl J Med.
1989;
321
1562-1566
- 39
Graham D Y, Malaty H M, Evans D G, et al.
Epidemiology of Helicobacter pylori in an asymptomatic population in the United States.
Effect of age, race, and socioeconomic status.
Gastroenterology.
1991;
100
1495-1501
- 40
Gasbarrini G, Pretolani S, Bonvicini F, et al.
A population based study of Helicobacter pylori infection in a European country: the
San Marino study. Relations with gastrointestinal diseases.
Gut.
1995;
36
838-844
- 41
Anonymous.
An international association between helicobacter pylori infection and gastric cancer.
The Eurogast study group.
Lancet.
1993;
341
1359-1362
- 42
Goodman K J, Correa P.
The transmission of Helicobacter pylori. A critial review of the evidence.
Int J Epidemiol.
1995;
24
875-887
- 43
Kuipers E J, Pena A S, Van Kamp G, et al.
Seroconversion for Helicobacter pylori infection.
Lancet.
1993;
342
328-331
- 44
Megraud F.
Epidemiology of Helicobacter pylori infection: where are we in 1995?.
Eur J Gastroenterol Hepatol.
1995;
7
292-295
- 45
Graham D Y, Lew G M, Klein P D, et al.
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of
gastric or duodenal ulcer. A randomized, controlled study.
Ann Intern Med.
1992;
116
705-708
- 46
Peterson W L.
Helicobacter pylori and peptic ulcer disease (see comments). (Review) (97 refs).
N Engl J Med.
1991;
324
1043-1048
- 47
Rauws E A.
Role of Helicobacter pylori in duodenal ulcer.
Drugs.
1992;
44
921-927
- 48
Hentschel E, Brandstatter G, Dragosics B, et al.
Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter
pylori and the recurrence of duodenal ulcer.
N Engl J Med.
1993;
328
308-312
- 49
Veldhuyzen van Zanten S J, Sherman P M.
Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer
and nonulcer dyspepsia: a systematic overview.
Can Med Assoc J.
1994;
150
177-185
- 50
Elta G H, Scheiman J M, Barnett J L, et al.
Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia patients.
Am J Gastroenterol.
1995;
90
1089-1093
- 51
Greenberg R E, Bank S.
The prevalence of Helicobacter pylori in nonulcer dyspepsia. Importance of stratification
according to age.
Arch Intern Med.
1990;
150
2053-2055
- 52
Holtmann G, Goebell H, Holtmann M, Talley N J.
Dyspepsia in healthy blood donors. Pattern of symptoms and association with Helicobacter
pylori.
Dig Dis Sci.
1994;
39
1090-1098
- 53
Bouche O.
Should Helicobacter pylori be eradicated in a patient with chronic gastritis? (Review)
(127 refs) (French).
Gastroenterol Clin Biol.
1996;
20
S143-153
- 54
Armstrong D.
Helicobacter pylori infection and dyspepsia.
Scand J Gastroenterol Suppl.
1996;
215
38-47
- 55
McCarthy C, Patchett S, Collins R M, et al.
Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia.
Dig Dis Sci.
1995;
40
114-119
- 56
Gilvarry J, Buckley M J, Beattie S, et al.
Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia.
Scan J Gastroenterol.
1997;
32
535-540
- 57
Sheu B S, Lin C Y, Lin X Z, et al.
Long-term outcome of triple therapy in Helicobacter pylori-related nonulcer dyspepsia:
a prospective controlled assessment.
Am J Gastroenterol.
1996;
91
441-447
- 58
Lazzaroni M, Bargiggia S, Sangaletti O, et al.
Eradication of Helicobacter pylori and long-term outcome of functional dyspepsia.
A clinical endoscopic study.
Dig Dis Sci.
1996;
41
1589-1594
- 59
O'Morain C, Gilvarry J.
Eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. (Review)
(40 rfs).
Scand J Gastroenterol Suppl.
1993;
196
30-33
- 60
Veldhuyzen van Zanten S J, Malatjalian D.
The effect of eradication of Helicobacter pylori on symptoms of non-ulcer dyspepsia
(NUD): a randomized, double blind, placebo-controlled trial (abstract).
Gastroenterology.
1995;
108
A250
- 61
Greenberg P D.
Prospective, double-blind treatment of Helicobacter pylori in patients with non-ulcer
dyspepsia. (Abstract).
Gastroenterology.
1996;
110
A123
- 62
Schubert T T, Schubert A B, Ma C K.
Symptoms, gastritis, and Helicobacter pylori in patients referred for endoscopy.
Gastrointest Endosc.
1992;
38
357-360
- 63
McColl K EL.
U.K. MRC trial of H. pylori eradication therapy for non-ulcer dyspepsia. (Abstract).
Gastroenterology.
1998;
114
A222-222
- 64
Koelz H R.
Treatment of Helicobacter pylori does not improve symptoms of functional dyspepsia.
(Abstract).
Gastroenterology.
1998;
114
A182-182
- 65
Bretagne J F.
The course of symptoms after eradication of Helicobacter pylori: a one-year follow-up
of a cohort of 258 patients with duodenal ulcer or nonulcer dyspepsia. (Abstract).
Gastroenterology.
1998;
114
A81-81
- 66
Talley N J.
Long-term follow-up of patients with non-ulcer dyspepsia after Helicobacter pylori
eradication. A randomized double-blind placebo-controlled trial. (Abstract).
Gastroenterology.
1998;
114
A305-305
- 67
Anonymous.
Nih consensus conference. Helicobacter pylori in peptic ulcer disease. Nih consensus
development panel on Helicobacter pylori in peptic ulcer disease.
J Am Med Ass.
1994;
272
65-69
- 68 Dyspepsia Management Guidelines. Brit Society of Gastroenterology. http://www.bsg.org.uk/clinical/data/dmg.htm;
1996
- 69
Wilcox C M, Schwartz D A.
Endoscopic characterization of idiopathic esophageal ulceration associated with human
immunodeficiency virus infection.
J Clin Gastroenterol.
1993;
16
251-256
- 70
Megraud F.
Advantages and disadvantages of current diagnostic tests for the detection of Helicobacter
pylori.
Scand J Gastroenterol Suppl.
1996;
215
57-62
- 71
Ateshkadi A, Lam N P, Johnson C A.
Helicobacter pylori and peptic ulcer disease.
Clin Pharmacy.
1993;
12
34-48
- 72
Laine L, Chun D, Stein C, et al.
The influence of size or number of biopsies on rapid urease test results: a prospective
evaluation.
Gastrointest Endosc.
1996;
43
49-53
- 73
Loy C T, Irwig L M, Katelaris P H, Talley N J.
Do commercial serological kits for Helicobacter pylori infection differ in accuracy?
A meta-analysis.
Am J Gastroenterol.
1996;
91
1138-1144
- 74
Megraud F.
The most important diagnostic modalities for Helicobacter pylori, now and in the future.
(Review) (4 refs).
Eur J Gastroenterol Hepatol.
1997;
1
S13-15
- 75
Malfertheiner P, Megraud F, O'Morain C, et al.
Current european concepts in the management of Helicobacter pylori infection - the
Maastricht consensus report. The European Helicobacter pylori study group.
Eur J Gastroenterol Hepatol.
1997;
9
1-2
- 76
Soll A H.
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines.
Practice parameters committee of the American College of Gastroenterology.
J Am Med Ass.
1996;
275
622-629
- 77
Holtmann G, Layer P, Goebell H.
Proton-pump inhibitors or h2-receptor antagonists for Helicobacter pylori eradication
- a meta-analysis (letter).
Lancet.
1996;
347
763
- 78
Labenz J, Gyenes E, Ruhl G H, Borsch G.
Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter
pylori.
Am J Gastroenterol.
1993;
88
491-495
- 79
Fennerty M B, Lieberman D, Magaret N, et al.
Effectiveness of H. pylori treatment regimens in clinical practice: a community-based
outcomes study. (Abstract).
Gastroenterology.
1997;
112
A14-14
- 80
Lee J, O'Morain C.
Consensus or confusion: a review of existing national guidelines on Helicobacter pylori-related
disease.
Eur J Gastroenterol Hepatol.
1997;
9
527-531
- 81
Rokkas T, Karameris A, Mavrogeorgis A, et al.
Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic
ulcer disease.
Gastrointest Endosc.
1995;
41
1-4
- 82
Graham D Y, Hepps K S, Ramirez F C, et al.
Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
Scan J Gastroenterol.
1993;
28
939-942
- 83
Jaspersen D, Koerner T, Schorr W, et al.
Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage.
Gastrointest Endosc.
1995;
41
5-7
- 84
Bayerdorffer E, Neubauer A, Rudolph B, et al.
Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after
cure of Helicobacter pylori infection. MALT Lymphoma Study Group.
Lancet.
1995;
345
1591-1594
- 85
Wotherspoon A C, Doglioni C, Diss T C, et al.
Regression of primary low-grade-B-cell gastric lymphoma of mucosa-associated lymphoid
tissue type after eradication of Helicobacter pylori.
Lancet.
1993;
342
575-577
- 86
Sackmann M, Morgner A, Rudolph B, et al.
Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted
by endosonographic staging.
Gastroenterology.
1997;
113
1087-1090
- 87
Veldhuyzen von Z S, Sherman P M, Hunt R H.
Helicobacter pylori: new developments and treatments.
CMAJ.
1997;
156
1565-1574
- 88
Lerang F, Moum B, Ragnhildstveit E, et al.
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy
for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr
follow-up study.
Am J Gastroenterol.
1997;
92
653-658
- 89
Hopkins R J, Girardi L S, Turney E A, et al.
Relationship between Helicobacter pylori eradication and reduced duodenal and gastric
ulcer recurrence: a review.
Gastroenterology.
1996;
110
1244-1252
- 90
Vanderhulst R M, Rauws E J, Koycu B, et al.
Prevention of ulcer recurrence after eradication of Helicobacter pylori - A prospective
long-term follow-up study.
Gastroenterology.
1997;
113
1082-1086
- 91
Labenz J, Blum A L, Bayerdorffer E, et al.
Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux
esophagitis.
Gastroenterology.
1997;
112
1442-1447
- 92
Forbes G M, Glaser M E, Cullen D J, et al.
Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up.
Lancet.
1994;
343
258-260
- 93
Goulston K J, Dent O F, Logan J, et al.
Use of H2-receptor antagonists in patients with dyspepsia and heartburn: a cost comparison.
Med J Aust.
1991;
155
20-26
- 94
Goodson J D, Lehmann J W, Richter J M, et al.
Is upper gastrointestinal radiography necessary in the initial management of uncomplicated
dyspepsia? A randomized controlled trial comparing empiric antacid therapy plus patient
reassurance with traditional care.
J Gen Intern Med.
1989;
4
367-374
- 95
Bytzer P, Hansen J M, Schaffalitzky de Muckadell O B.
Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia.
Lancet.
1994;
343
811-816
- 96
Bloom B S.
Cross-national changes in the effects of peptic ulcer disease.
Ann Intern Med.
1991;
114
558-562
- 97
Westbrook J I, Rushworth R L.
The epidemiology of peptic ulcer mortality 1953 - 1989: a birth cohort analysis.
Intern J Epidemiol.
1993;
22
1085-1092
- 98
La Vecchia C, Lucchini F, Negri E, et al.
The impact of therapeutic improvements in reducing peptic ulcer mortality in Europe.
Intern J Epidemiol.
1993;
22
96-106
- 99
Msika S, Tazi M A, Benhamiche A M, et al.
Population-based study of diagnosis, treatment and prognosis of gastric cancer.
Brit J Surg.
1997;
84
1474-1478
- 100
Kahn K.
Endoscopy in the evaluation of dyspepsia. Health and Public Policy Committee, American
College of Physicians.
Ann Intern med.
1985;
102
266-269
- 101
American Society for Gastrointestinal Endoscopy.
The role of endoscopy in the management of the patient with peptic ulcer disease.
Guidelines for clinical application.
Gastrointest Endosc.
1988;
34
4-25S
- 102
Bytzer P.
Diagnosing dyspepsia: any controversies left?.
Gastroenterology.
1996;
110
302-306
- 103
Tham T C.
Application of serological screening for Helicobacter pylori in reducing endoscopy
workload.
Gastroenterology.
1993;
104
A26
- 104
Lassen A T.
H. Pylori “test and treat” or prompt endoscopy for dyspeptic patients in primary care.
A randomized controlled trial of two management strategies: one year follow-up. (Abstract).
Gastroenterology.
1998;
114
A196-196
- 105
Jones R H.
A Helicobacter test and treat strategy: costs and outcomes in a randomized controlled
trial in primary care. (Abstract).
Gastroenterology.
1998;
114
A20-20
- 106
Ofman J J, Etchason J, Fullerton S, et al.
Management strategies for Helicobacter pylori-seropositive patients with dyspepsia
- clinical and economic consequences.
Ann Intern Med.
1997;
126
280-291
- 107
Briggs A H, Sculpher M J, Logan R P, et al.
Cost effectiveness of screening for and eradication of Helicobacter pylori in management
of dyspeptic patients under 45 years of age.
Br Med J.
1996;
312
1321-1325
- 108
Fullerton F.
Empiric antibiotic therapy versus early endoscopy in dyspeptic patients with positive
serologic test for Helicobacter pylori: a decision analysis. (Abstract).
Gastroenterology.
1995;
108
A15
- 109
Silverstein F E, Graham D Y, Senior J R, et al.
Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid
arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind,
placebo-controlled trial.
Ann Intern Med.
1995;
123
241-249
- 110
Fendrick A M, Chernew M E, Hirth R A, Bloom B S.
Immediate endoscopy or initial Helicobacter pylori serological testing for suspected
peptic ulcer disease: estimating cost-effectiveness using decision analysis.
Yale Journal of Biology & Medicine.
1996;
69
187-195
- 111
Eckardt V F, Giessler W, Kanzler G, Bernhard G.
Does endoscopic follow-up improve the outcome of patients with benign gastric ulcers
and gastric cancer?.
Cancer.
1992;
69
301-305
- 112
Farinati F, Cardin F, Di Mario F, et al.
Early and advanced gastric cancer during follow-up of apparently benign gastric ulcer:
significance of the presence of epithelial dysplasia.
J Surg Oncol.
1987;
36
263-267
- 113
Tragardh B, Haglund U.
Endoscopic diagnosis of gastric ulcer. Evaluation of the benefits of endoscopic follow-up
observation for malignancy.
Acta Chir Scand.
1985;
15
37-41
- 114
Bytzer P.
Endoscopic follow-up study of gastric ulcer to detect malignancy: is it worthwhile?.
Scandinavian Journal of Gastroenterology.
1991;
26
1193-1199
- 115
Pruitt R E, Truss C D.
Endoscopy, gastric ulcer, and gastric cancer. Follow-up endoscopy for all gastric
ulcers?.
Dig Dis Sci.
1993;
38
284-288
- 116
Hansson L E, Nyren O, Hsing A W, et al.
The risk of stomach cancer in patients with gastric or duodenal ulcer disease.
N Engl J Med.
1996;
335
242-249
- 117
Talley N J, Evans J M, Fleming K C, et al.
Nonsteroidal antiinflammatory drugs and dyspepsia in the elderly.
Dig Dis Sci.
1995;
40
1345-1350
- 118
Graham D Y.
Treatment of peptic ulcers caused by Helicobacter pylori (editorial; comment).
N Engl J Med.
1993;
328
349-350
- 119
Gabriel S E, Jaakkimainen L, Bombardier C.
Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory
drugs. A meta-analysis.
Ann Intern Med.
1991;
115
787-796
- 120
Larkai E N, Smith J L, Lidsky M D, Graham D Y.
Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic
nonsteroidal anti-inflammatory drug use.
Am J Gastroenterol.
1987;
82
1153-1158
- 121
Battistini B, Botting R, Bakhle Y S.
COX-1 and COX-2: toward the development of more selective NSAIDs.
Drug News and Perspectives (Barcelona).
1994;
7
501-512
- 122
Distel M, Mueller C, Bluhmki E, Fries J.
Safety of meloxicam: a global analysis of clinical trials.
Brit J Rheumatol.
1996;
35
68-77
- 123
Roth S H, Bennett R, Caldron P, et al.
A longterm endoscopic evaluation of patients with arthritis treated with nabumetone
vs naproxen.
J Rheumatol.
1994;
21
1118-1123
- 124
Porro G B, Montrone F, Petrillo M, et al.
Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic
patients.
Am J Gastroenterol.
1995;
90
1485-1488
- 125
Allison M C, Howatson A G, Torrance C J, et al.
Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs
(see comments).
N Engl J Med.
1992;
327
749-754
- 126
Graham D Y, Lidsky M D, Cox A M, et al.
Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection.
Gastroenterology.
1991;
100
653-657
- 127
Loeb D S, Talley N J, Ahlquist D A, et al.
Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role
of Helicobacter pylori.
Gastroenterology.
1992;
102
1899-1905
- 128
Chan F K, Sung J J, Chung S C, et al.
Randomized trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory
drug therapy to prevent peptic ulcers.
Lancet.
1997;
350
975-979
- 129
Lai K C.
Eradication of Helicobacter pylori did not accelerate the healing of gastric and duodenal
ulcers/erosions in patients on long-term continuous nonsteroidal anti-inflammatory
drugs. (Abstract).
Gastroenterology.
1998;
114
A192
- 130
Lai K C.
Can eradication of Helicobacter Pylori prevent future development of peptic ulcers
in patients receiving long-term continuous nonsteroidal anti-inflammatory drugs. (Abstract).
Gastroenterology.
1998;
114
A192
- 131
Hawkey C J, Tullassay Z.
Failure of Helicobacter Pylori eradication to influence site-specific relapse in high
risk NSAID users: results of a large six month double blind randomized controlled
clinical trial. (Abstract).
Gastroenterology.
1998;
114
A145
- 132
Koch M, Dezi A, Ferrario F, Capurso L.
Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal
injury - a meta-analysis of randomized controlled clincal trials. (Abstract).
Arch Intern Med.
1996;
156
2321-2332
- 133
Taha A S, Hudson N, Hawkey C J, et al.
Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal
antiinflammatory drugs.
N Engl J Med.
1996;
334
1435-1439
- 134
Agrawal N M, Van Kerckhove H E, Erhardt L J, Geis G S.
Misoprostol coadministered with diclofenac for prevention of gstroduodenal ulcers.
a one-year study.
Dig Dis Sci.
1995;
40
1125-1131
- 135
Hudson N, Taha A S, Russell R I, et al.
Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated
gastroduodenal ulceration (see comments).
Gastroenterology.
1997;
112
1817-1822
- 136
Ekstrom P, Carling L, Wetterhus S, et al.
Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving
continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study.
Scan J Gastroenterol.
1996;
31
753-758
- 137
Yeomans N D, Tulassay Z, Juhasz L, et al.
A Comparison of Omeprazole with Ranitidine for Ulcers Associated with Nonsteroidal
Antiinflammatory Drugs.
N Engl J Med.
1998;
338
719-726
- 138
Hawkey C J, Karrasch J A, Szczepanski L, et al.
Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory
Drugs.
N Engl J Med.
1998;
338
727-734
- 139
Martin L F.
Stress ulcers are common after aortic surgery. Endoscopy evaluation of prophylactic
therapy.
Am Surg.
1994;
60
169-174
- 140
Cook D J, Reeve B K, Guyatt G H, et al.
Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses.
J Am Med Ass.
1996;
275
308-314
- 141
Zandstra D F, Stoutenbeek C P.
The virtual absence of stress-ulceration related bleeding in ICU patients receiving
prolonged mechanical ventilation without any prophylaxis. A prospective cohort study
(see comments).
Intens Care Med.
1994;
20
335-340
- 142
Cook D J, Fuller H D, Guyatt G H, et al.
Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical
Care Trials Group.
N Engl J Med.
1994;
330
377-381
- 143
Levy M J, Seelig C B, Robinson N J, Ranney J E.
Comparison of omeprazole and ranitidine for stress ulcer prophylaxis.
Dig Dis Sci.
1997;
42
1255-1259
- 144
Schepp W, Schusdziarra V, Classen M.
(Stress ulcer prophylaxis 1995. Balancing between gastrointestinal bleeding and nosocomial
pneumonia.)
Dtsch Med Wochenstr.
1995;
120
573-579
- 145
Marrone G C, Silen W.
Pathogenesis, diagnosis and traetment of acute gastric mucosal lesions.
Clin Gastroenterol.
1984;
13
635-650
- 146
De Bosset V, Gonvers J J, Froehlich F, et al.
Appropriateness of gastroscopy: Bleeding and dysphagia.
Endoscopy.
1999;
31
615-622
- 147
Hudson N.
Excess long-term mortality in patients with ulcer complications.
Lancet.
1997;
349
968-969
- 148
Svanes C, Lie R T, Lie S A, et al.
Survival after peptic ulcer perforation: a time trend analysis.
J Clin Epidemiol.
1996;
49
1363-1371
- 149
Svanes C, Salvesen H, Stangeland L, et al.
Perforated peptic ulcer over 56 years. Time trends in patients and disease characteristics.
Gut.
1993;
3
1666-1671
- 150 International Agency for Research on Cancer.
Atlas of cancer mortality in the European Economic Community. In: Smans M, Muir CS, Boyle P (eds). Lyon, France; IARC, 1992
- 151 International Agency for Research on Cancer.
Atlas of cancer mortality in Central Europe. In: Zatonski W, Smans M, Tyczynski J, et al. (eds). Lyon, France; IARC, 1996
- 152
Fuchs C S, Mayer R J.
Gastric carcinoma.
N Engl J Med.
1995;
333
32-41
- 153
Gasbarrini G, Genta R M, Anti M, et al.
Update on Helicobacter pylori research. Malignancies.
Eur J Gastroenterol Hepatol.
1997;
9
621-623
- 154
Forman D, Newell D G, Fullerton F, et al.
Association between infection with Helicobacter pylori and risk of gastric cancer:
evidence from a prospective investigation.
Brit Med J.
1991;
302
1302-1305
- 155
Parsonnet J, Friedman G D, Vandersteen D P, et al.
Helicobacter pylori infection and the risk of gastric carcinoma.
N Engl J Med.
1991;
325
1127-1131
- 156
Nomura A, Stemmermann G N, Chyou P H, et al.
Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii.
N Engl J Med.
1991;
325
1132-1136
- 157
Blaser M J, Chyou P H, Nomura A.
Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric
ulcer, and duodenal ulcer risk.
Cancer Res.
1995;
55
562-565
- 158
Matley P J, Dent D M, Madden M V, et al.
Gastric carcinoma in young adults.
Ann Surg.
1988;
208
593-596
- 159
Moreno-Otero R, Rodriguez S, Carbo J, et al.
Acute upper gastrointestinal bleeding as primary symptom of gastric carcinoma.
J Surg Oncol.
1987;
36
130-133
- 160
Schlemper R J, Itabashi M, Kato Y, et al.
Differences in diagnostic criteria for gastric carcinoma between Japanese and Western
pathologists.
Lancet.
1997;
349
1725-1729
- 161
Farinati F, Rugge M, Di Mario F, et al.
Early and advanced gastric cancer in the follow-up of moderate and severe gastric
dysplasia patients. a prospective study. i. g. g. e. d.-interdisciplinary group on
gastric epithelial dysplasia.
Endoscopy.
1993;
25
261-264
- 162
Hallissey M T, Allum W H, Jewkes A J, et al.
Early detection of gastric cancer.
Brit Med J.
1990;
301
513-515
- 163
Caprilli R, Andreoli A, Capurso L, et al.
Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative
recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto
(GISC).
Alimentary Pharmacology & Therapeutics.
1994;
8
35-43
- 164
Iwao T, Toyonaga A, Ikegami M, et al.
McCormack's endoscopic signs for diagnosing portal hypertension: comparison with gastroesophageal
varices.
Gastrointest Endosc.
1994;
40
470-473
- 165
Ziegler K, Sanft C, Zimmer T, et al.
Comparison of computed tomography, endosonography, and intraoperative assessment in
tn staging of gastric carcinoma.
Gut.
1993;
34
604-610
- 166
Dittler H J, Siewert J R.
Role of endoscopic ultrasonography in gastric carcinoma.
Endoscopy.
1993;
25
162-166
- 167
Grimm H, Binmoeller K F, Hamper K, et al.
Endosonography for preoperative locoregional staging of esophageal and gastric cancer.
Endoscopy.
1993;
25
224-230
1 The European Panel on Appropriateness of Gastrointestinal Endoscopy (EPAGE, Lausanne,
Switzerland)
Florian FroehlichMD PD
Policlinique Médicale Universitaire
Rue César-Roux 19
CH-1005 Lausanne
Switzerland
Phone: +41-32-466 29 55
Email: florian.froehlich@bluewin.ch
